Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
coloproctology
Erschienen in: coloproctology 3/2016

02.11.2015 | Übersichten

Hidradenitis suppurativa/​Acne inversa

Ein Update

verfasst von: J. Kirschke, S. Hessam, Prof. Dr. F. G. Bechara

Erschienen in: coloproctology | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Zusammenfassung

Hidradenitis suppurativa/Acne inversa (HS/AI) ist eine chronische, inflammatorische Hauterkrankung, die sich durch schmerzhafte Knoten, Abszesse, Fisteln und Vernarbungen auszeichnet und zu deutlichen funktionellen sowie psychologischen Beeinträchtigungen bei den betroffenen Patienten führen kann. Es vergehen oft Jahre, bis die richtige Diagnose gestellt wird. Die Behandlung der HS/AI stellt weiterhin eine Herausforderung dar. Konservative Therapien können in initialen Stadien der Erkrankung zu einer Besserung, nicht aber Heilung der Erkrankung führen. Bei fortgeschrittenen Stadien bleibt die radikale Exzision weiterhin die Therapie der Wahl.
Literatur
1.
Adams DR, Yankura JA, Fogelberg AC et al (2010) Treatment of hidradenitis suppurativa with etanercept injection. Arch Dermatol 146:501–504PubMed
2.
Al-Ali FMS, Ratnamala U, Mehta TY et al (2010) Hidradenitis suppurativa (or Acne inversa) with autosomal dominant inheritance is not linked to chromosome 1p21.1–1q25.3 region. Exp Dermatol 19:851–853PubMedCrossRef
3.
Alikhan A, Lynch PJ, Eisen DB (2009) Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol 60:539–561. (quiz 562–533)
4.
Amano M, Grant A, Kerdel FA (2010) A prospective open-label clinical trial of adalimumab for the treatment of hidradenitis suppurativa. Int J Dermatol 49:950–955PubMedCrossRef
5.
Arenbergerova M, Gkalpakiotis S, Arenberger P (2010) Effective long-term control of refractory hidradenitis suppurativa with adalimumab after failure of conventional therapy. Int J Dermatol 49:1445–1449PubMedCrossRef
6.
Barth JH, Layton AM, Cunliffe WJ (1996) Endocrine factors in pre- and postmenopausal women with hidradenitis suppurativa. Br J Dermatol 134:1057–1059PubMedCrossRef
7.
8.
9.
Bendahan J, Paran H, Kolman S et al (1992) The possible role of Chlamydia trachomatis in perineal suppurative hidradenitis. Eur J Surg 158:213–215PubMed
10.
Blok JL, Van Hattem S, Jonkman MF et al (2013) Systemic therapy with immunosuppressive agents and retinoids in hidradenitis suppurativa: a systematic review. Br J Dermatol 168:243–252PubMedCrossRef
11.
Boer J, Nazary M (2011) Long-term results of acitretin therapy for hidradenitis suppurativa. Is acne inversa also a misnomer? Br J Dermatol 164:170–175PubMedCrossRef
12.
Brocard A, Knol A-C, Khammari A et al (2007) Hidradenitis suppurativa and zinc: a new therapeutic approach. A pilot study. Dermatology 214:325–327PubMedCrossRef
13.
Canoui-Poitrine F, Revuz JE, Wolkenstein P et al (2009) Clinical characteristics of a series of 302 French patients with hidradenitis suppurativa, with an analysis of factors associated with disease severity. J Am Acad Dermatol 61:51–57PubMedCrossRef
14.
Chen YE, Gerstle T, Verma K et al (2014) Management of hidradenitis suppurativa wounds with an internal vacuum-assisted closure device. Plast Reconstr Surg 133:370e-377ePubMedCrossRef
15.
Constantinou C, Widom K, Desantis J et al (2008) Hidradenitis suppurativa complicated by squamous cell carcinoma. Am Surg 74:1177–1181PubMed
16.
Cosmatos I, Matcho A, Weinstein R et al (2013) Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States. J Am Acad Dermatol 68:412–419PubMedCrossRef
17.
Danby FW, Jemec GBE, Marsch WC et al (2013) Preliminary findings suggest hidradenitis suppurativa may be due to defective follicular support. Br J Dermatol 168:1034–1039PubMedCrossRef
18.
Deckers IE, Van Der Zee HH, Boer J et al (2015) Correlation of early-onset hidradenitis suppurativa with stronger genetic susceptibility and more widespread involvement. J Am Acad Dermatol 72:485–488PubMedCrossRef
19.
Downs A (2004) Smoothbeam laser treatment may help improve hidradenitis suppurativa but not Hailey-Hailey disease. J Cosmet Laser Ther 6:163–164PubMedCrossRef
20.
Dreno B, Khammari A, Brocard A et al (2012) Hidradenitis suppurativa: the role of deficient cutaneous innate immunity. Arch Dermatol 148:182–186PubMedCrossRef
21.
Durmaz R, Tekerekoǧlu MS, Kalcioǧlu T et al (2001) Nasal carriage of methicillin-resistant Staphylococcus aureus among smokers and cigarette factory workers. New Microbiol 24:143–147PubMed
22.
Emelianov VU, Bechara FG, Gläser R et al (2012) Immunohistological pointers to a possible role for excessive cathelicidin (LL-37) expression by apocrine sweat glands in the pathogenesis of hidradenitis suppurativa/acne inversa. Br J Dermatol 166:1023–1034PubMedCrossRef
23.
Estrach S, Cordes R, Hozumi K et al (2008) Role of the Notch ligand Delta1 in embryonic and adult mouse epidermis. J Invest Dermatol 128:825–832PubMedCrossRef
24.
Fain JN (2006) Release of interleukins and other inflammatory cytokines by human adipose tissue is enhanced in obesity and primarily due to the nonfat cells. Vitam Horm 74:443–477PubMedCrossRef
25.
Fitzsimmons JS, Guilbert PR, Fitzsimmons EM (1985) Evidence of genetic factors in hidradenitis suppurativa. Br J Dermatol 113:1–8PubMedCrossRef
26.
Gao M, Wang P-G, Cui Y et al (2006) Inversa acne (hidradenitis suppurativa): a case report and identification of the locus at chromosome 1p21.1–1q25.3. J Invest Dermatol 126:1302–1306PubMedCrossRef
27.
Gener G, Canoui-Poitrine F, Revuz JE et al (2009) Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients. Dermatology 219:148–154PubMedCrossRef
28.
Giamarellos-Bourboulis EJ, Antonopoulou A, Petropoulou C et al (2007) Altered innate and adaptive immune responses in patients with hidradenitis suppurativa. Br J Dermatol 156:51–56PubMedCrossRef
29.
Girouard SD, Falk RH, Rennke HG et al (2012) Hidradenitis suppurativa resulting in systemic amyloid A amyloidosis: a case report and review of the literature. Dermatol Online J 18:2PubMed
30.
Grant A, Gonzalez T, Montgomery MO et al (2010) Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol 62:205–217PubMedCrossRef
31.
Gulliver WP, Jemec GBE, Baker KA (2012) Experience with ustekinumab for the treatment of moderate to severe hidradenitis suppurativa. J Eur Acad Dermatol Venereol 26:911–914PubMedCrossRef
32.
Hana A, Booken D, Henrich C et al (2007) Functional significance of non-neuronal acetylcholine in skin epithelia. Life Sci 80:2214–2220PubMedCrossRef
33.
Harrison BJ, Mudge M, Hughes LE (1987) Recurrence after surgical treatment of hidradenitis suppurativa. Br Med J (Clin Res Ed) 294:487–489CrossRef
34.
Hazen PG, Hazen BP (2010) Hidradenitis suppurativa: successful treatment using carbon dioxide laser excision and marsupialization. Dermatol Surg 36:208–213PubMedCrossRef
35.
Hessam S, Sand M, Georgas D et al (2013) Laserepilation bei Hidradenitis suppurativa/Acne inversa und Pilonidalsinus. Aktuelle Derm 39:268–277CrossRef
36.
Highton L, Chan W-Y, Khwaja N et al (2011) Treatment of hidradenitis suppurativa with intense pulsed light: a prospective study. Plast Reconstr Surg 128:459–465PubMedCrossRef
37.
38.
Hurley H (1996) Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa and familial benign pemphigus. Surgical approach. In: Roenigk R, Roenigk H (Hrsg) Roenigk & Roenigk’s dermatologic surgery: principles and practice, 2. Aufl. Marcel Dekker, New york, S 623–664
39.
Jahns AC, Killasli H, Nosek D et al (2014) Microbiology of hidradenitis suppurativa (acne inversa): a histological study of 27 patients. APMIS 122:804–809PubMedCrossRef
40.
Jain V, Jain A (2012) Use of lasers for the management of refractory cases of hidradenitis suppurativa and pilonidal sinus. J Cutan Aesthet Surg 5:190–192PubMedPubMedCentralCrossRef
41.
42.
43.
Jemec GB, Gottlieb A, Forman S (2014) Efficacy and Safety of Adalimumab in patients with moderate to severe hidradenitis suppurativa: Results from PIONEER II, a Phase 3, randomized, placebo-controlled trial. In: 23rd congress of the EADV, Amsterdam 2014. Abstract FC08.2
44.
Jemec GB, Gniadecka M (1997) Sebum excretion in hidradenitis suppurativa. Dermatology 194:325–328PubMedCrossRef
45.
Jemec GB, Wendelboe P (1998) Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J Am Acad Dermatol 39:971–974PubMedCrossRef
46.
Jemec GB, Heidenheim M, Nielsen NH (1996) The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol 35:191–194PubMedCrossRef
47.
Jemec GB, Gottlieb A, Forman S et al (2014) Efficacy and Safety of Adalimumab in Patients with Moderate to Severe Hidradenitis Suppurativa: Results from PIONEER II, a Phase 3, Randomized, Placebo-Controlled Trial. Abstract FC08.2. 23rd Congress of the European Dermatology and Venereology (EADV) Meeting, Amsterdam, Netherlands 2014
48.
Jeong SH, Park JH, Kim JN et al (2010) Up-regulation of TNF-alpha secretion by cigarette smoke is mediated by Egr-1 in HaCaT human keratinocytes. Exp Dermatol 19:e206–212PubMedCrossRef
49.
Join-Lambert O, Coignard H, Jais J-P et al (2011) Efficacy of rifampin-moxifloxacin-metronidazole combination therapy in hidradenitis suppurativa. Dermatology 222:49–58PubMedCrossRef
50.
Joseph MA, Jayaseelan E, Ganapathi B et al (2005) Hidradenitis suppurativa treated with finasteride. J Dermatolog Treat 16:75–78PubMedCrossRef
51.
Kathju S, Lasko LA, Stoodley P (2012) Considering hidradenitis suppurativa as a bacterial biofilm disease. FEMS Immunol Med Microbiol 65:385–389PubMedCrossRef
52.
Kimball AB, Kerdel F, Adams D et al (2012) Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med 157:846–855PubMedCrossRef
53.
Kimball A, Zouboulis CC, Armstrong AW et al (2014) Safety and Efficacy of Adalimumab in Patients with Moderate to Severe Hidradenitis Suppurativa: Results from First 12 Weeks of PIONEER I, a Phase 3, Randomized, Placebo-Controlled Trial. Abstract #210. 44th Annual Meeting of the European Society for Dermatological Research (ESDR), Copenhagen, Denmark. http://​www.​nature.​com/​jid/​journal/​v134/​n2s/​full/​jid2014340a.​html
54.
Kintz P, Henrich A, Cirimele V et al (1998) Nicotine monitoring in sweat with a sweat patch. J Chromatogr B Biomed Sci Appl 705:357–361PubMedCrossRef
55.
Konety BR, Cooper T, Flood HD et al (1996) Scrotal elephantiasis associated with hidradenitis suppurativa. Plast Reconstr Surg 97:1243–1245PubMedCrossRef
56.
König A, Lehmann C, Rompel R et al (1999) Cigarette smoking as a triggering factor of hidradenitis suppurativa. Dermatology 198:261–264PubMedCrossRef
57.
Kraft JN, Searles GE (2007) Hidradenitis suppurativa in 64 female patients: retrospective study comparing oral antibiotics and antiandrogen therapy. J Cutan Med Surg 11:125–131PubMedCrossRef
58.
Kurek A, Johanne Peters EM, Sabat R et al (2013) Depression is a frequent co-morbidity in patients with acne inversa. J Dtsch Dermatol Ges 11:743–749, 743–750PubMed
59.
Kurzen H, Wessler I, Kirkpatrick CJ et al (2007) The non-neuronal cholinergic system of human skin. Horm Metab Res 39:125–135PubMedCrossRef
60.
Kurzen H, Kurokawa I, Jemec GBE et al (2008) What causes hidradenitis suppurativa? Exp Dermatol 17:455–456 (discussion 457–472)PubMedCrossRef
61.
Lapins J, Jarstrand C, Emtestam L (1999) Coagulase-negative staphylococci are the most common bacteria found in cultures from the deep portions of hidradenitis suppurativa lesions, as obtained by carbon dioxide laser surgery. Br J Dermatol 140:90–95PubMedCrossRef
62.
Lefort K, Mandinova A, Ostano P et al (2007) Notch1 is a p53 target gene involved in human keratinocyte tumor suppression through negative regulation of ROCK1/2 and MRCKα kinases. Genes Dev 21:562–577PubMedPubMedCentralCrossRef
63.
Leslie KS, Tripathi SV, Nguyen TV et al (2014) An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa. J Am Acad Dermatol 70:243–251PubMedCrossRef
64.
Li T, Wen H, Brayton C et al (2007) Epidermal growth factor receptor and notch pathways participate in the tumor suppressor function of gamma-secretase. J Biol Chem 282:32264–32273PubMedCrossRef
65.
Lowell S, Jones P, Le Roux I et al (2000) Stimulation of human epidermal differentiation by Delta-Notch signalling at the boundaries of stem-cell clusters. Curr Biol 10:491–500PubMedCrossRef
66.
Lunniss PJ, Jenkins PJ, Besser GM et al (1995) Gender differences in incidence of idiopathic fistula-in-ano are not explained by circulating sex hormones. Int J Colorectal Dis 10:25–28PubMedCrossRef
67.
Maclean GM, Coleman DJ (2007) Three fatal cases of squamous cell carcinoma arising in chronic perineal hidradenitis suppurativa. Ann R Coll Surg Engl 89:709–712PubMedPubMedCentralCrossRef
68.
Martin-Ezquerra G, Masferrer E, Masferrer-Niubò M et al (2015) Use of biological treatments in patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol 29:56–60PubMedCrossRef
69.
Matusiak L, Bieniek A, Szepietowski JC (2009) Increased serum tumour necrosis factor-alpha in hidradenitis suppurativa patients: is there a basis for treatment with anti-tumour necrosis factor-alpha agents? Acta Derm Venereol 89:601–603PubMedCrossRef
70.
Matusiak L, Bieniek A, Szepietowski JC (2014) Bacteriology of Hidradenitis suppurativa – which antibiotics are the treatment of choice? Acta Derm Venereol 94:699–702PubMedCrossRef
71.
Melnik BC, Plewig G (2013) Impaired Notch signalling: the unifying mechanism explaining the pathogenesis of hidradenitis suppurativa (acne inversa). Br J Dermatol 168:876–878PubMedCrossRef
72.
Mendonça CO, Griffiths CEM (2006) Clindamycin and rifampicin combination therapy for hidradenitis suppurativa. Br J Dermatol 154:977–978PubMedCrossRef
73.
Miller I, Lynggaard CD, Lophaven S et al (2011) A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa. Br J Dermatol 165:391–398PubMedCrossRef
74.
Mortaz E, Adcock IM, Ito K et al (2010) Cigarette smoke induces CXCL8 production by human neutrophils via activation of TLR9 receptor. Eur Respir J 36:1143–1154PubMedCrossRef
75.
76.
Mortimer PS, Dawber RP, Gales MA et al (1986) A double-blind controlled cross-over trial of cyproterone acetate in females with hidradenitis suppurativa. Br J Dermatol 115:263–268PubMedCrossRef
77.
Mühlstädt M, Bechara FG, Kunte C (2013) Acne inversa (hidradenitis suppurativa). Erkennen – Verstehen – Therapieren. Hautarzt 64:55–61 (quiz 62)PubMedCrossRef
78.
Ogawa R (2010) The most current algorithms for the treatment and prevention of hypertrophic scars and keloids. Plast Reconstr Surg 125:557–568PubMedCrossRef
79.
80.
Pan Y, Lin MH, Tian X et al (2004) gamma-secretase functions through Notch signaling to maintain skin appendages but is not required for their patterning or initial morphogenesis. Dev Cell 7:731–743PubMedCrossRef
81.
Paradela S, Rodriguez-Lojo R, Fernandez-Torres R et al (2012) Long-term efficacy of infliximab in hidradenitis suppurativa. J Dermatolog Treat 23:278–283PubMedCrossRef
82.
Pavia CS, Pierre A, Nowakowski J (2000) Antimicrobial activity of nicotine against a spectrum of bacterial and fungal pathogens. J Med Microbiol 49:675–676PubMedCrossRef
83.
Pink AE, Simpson MA, Desai N et al (2012) Mutations in the γ-Secretase Genes NCSTN, PSENEN, and PSEN1 Underlie Rare Forms of Hidradenitis Suppurativa (Acne Inversa). J Invest Dermatol 132:2459–2461PubMedCrossRef
84.
Pink AE, Simpson MA, Desai N et al (2013) γ-Secretase mutations in hidradenitis suppurativa: new insights into disease pathogenesis. J Invest Dermatol 133:601–607PubMedCrossRef
85.
Plewig G, Steger M (1989) Acne inversa (alias acne triad, acne tetrad or hidradenitis suppurativa). In: Marks R, Plewig G (Hrsg) Acne and related disorders. Martin Dunitz, London, S 345–357
86.
Poli F, Wolkenstein P, Revuz J (2010) Back and face involvement in hidradenitis suppurativa. Dermatology 221:137–141PubMedCrossRef
87.
Prasad AS (2008) Clinical, immunological, anti-inflammatory and antioxidant roles of zinc. Exp Gerontol 43:370–377PubMedCrossRef
88.
Proweller A, Tu L, Lepore JJ et al (2006) Impaired notch signaling promotes De novo squamous cell carcinoma formation. Cancer Res 66:7438–7444PubMedCrossRef
89.
Rambhatla PV, Lim HW, Hamzavi I (2012) A systematic review of treatments for hidradenitis suppurativa. Arch Dermatol 148:439–446PubMedCrossRef
90.
91.
Revuz JE, Canoui-Poitrine F, Wolkenstein P et al (2008) Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol 59:596–601PubMedCrossRef
92.
Sabat R, Chanwangpong A, Schneider-Burrus S et al (2012) Increased prevalence of metabolic syndrome in patients with Acne inversa. PLoS ONE 7:e31810PubMedPubMedCentralCrossRef
93.
Sartorius K, Lapins J, Emtestam L et al (2003) Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa. Br J Dermatol 149:211–213PubMedCrossRef
94.
Sartorius K, Emtestam L, Jemec GBE et al (2009) Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol 161:831–839PubMedCrossRef
95.
Sawers RS, Randall VA, Ebling FJ (1986) Control of hidradenitis suppurativa in women using combined antiandrogen (cyproterone acetate) and oestrogen therapy. Br J Dermatol 115:269–274PubMedCrossRef
96.
Scheinfeld N (2014) Hidradenitis suppurativa: A practical review of possible medical treatments based on over 350 hidradenitis patients. Dermatol Online J. 2014 Mar 17;20(3). pii: doj_21764
97.
Scheinfeld N (2014) A case of a patient with stage III familial hidradenitis suppurativa treated with 3 courses of infliximab and died of metastatic squamous cell carcinoma. Dermatol Online J 20
98.
Schlapbach C, Hänni T, Yawalkar N et al (2011) Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa. J Am Acad Dermatol 65:790–798PubMedCrossRef
99.
Sehgal VN, Verma P, Sawant S et al (2011) Contemporary surgical treatment of hidradenitis suppurativa (HS) with a focus on the use of the diode hair laser in a case. J Cosmet Laser Ther 13:180–190PubMedCrossRef
100.
Sharon VR, Garcia MS, Bagheri S et al (2012) Management of recalcitrant hidradenitis suppurativa with ustekinumab. Acta Derm Venereol 92:320–321PubMedCrossRef
101.
Shavit E, Dreiher J, Freud T et al (2015) Psychiatric comorbidities in 3207 patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol 29:371–376PubMedCrossRef
102.
Slade DEM, Powell BW, Mortimer PS (2003) Hidradenitis suppurativa: pathogenesis and management. Br J Plast Surg 56:451–461PubMedCrossRef
103.
Sotiriou E, Goussi C, Lallas A et al (2012) A prospective open-label clinical trial of efficacy of the every week administration of adalimumab in the treatment of hidradenitis suppurativa. J Drugs Dermatol 11:s15–20PubMed
104.
Tierney E, Mahmoud BH, Hexsel C et al (2009) Randomized control trial for the treatment of hidradenitis suppurativa with a neodymium-doped yttrium aluminium garnet laser. Dermatol Surg 35:1188–1198PubMedCrossRef
105.
Torii K, Saito C, Furuhashi T et al (2011) Tobacco smoke is related to Th17 generation with clinical implications for psoriasis patients. Exp Dermatol 20:371–373PubMedCrossRef
106.
Ulrich A, Hildebrandt U, Ulrich J (2014) Acne inversa: Einfluss assoziierter Faktoren auf den Schweregrad und das operative Ergebnis. Hautarzt 65:623–627PubMedCrossRef
107.
Van Der Zee HH, Prens EP (2013) Failure of anti-interleukin-1 therapy in severe hidradenitis suppurativa: a case report. Dermatology 226:97–100PubMedCrossRef
108.
Van Der Zee HH, Boer J, Prens EP et al (2009) The effect of combined treatment with oral clindamycin and oral rifampicin in patients with hidradenitis suppurativa. Dermatology 219:143–147PubMedCrossRef
109.
Van Der Zee HH, Prens EP, Boer J (2010) Deroofing: a tissue-saving surgical technique for the treatment of mild to moderate hidradenitis suppurativa lesions. J Am Acad Dermatol 63:475–480PubMedCrossRef
110.
Van Der Zee HH, De Ruiter L, Van Den Broecke DG et al (2011) Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1ß and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1ß. Br J Dermatol 164:1292–1298PubMedCrossRef
111.
Van Rappard DC, Leenarts MF, Meijerink-Van ’T, Oost L et al (2012) Comparing treatment outcome of infliximab and adalimumab in patients with severe hidradenitis suppurativa. J Dermatolog Treat 23:284–289PubMedCrossRef
112.
Vazquez BG, Alikhan A, Weaver AL et al (2013) Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota. J Invest Dermatol 133:97–103PubMedPubMedCentralCrossRef
113.
Verdolini R, Clayton N, Smith A et al (2013) Metformin for the treatment of Hidradenitis suppurativa: a little help along the way. J Eur Acad Dermatol Venereol 27:1101–1108
114.
Von Der Werth JM, Williams HC (2000) The natural history of hidradenitis suppurativa. J Eur Acad Dermatol Venereol 14:389–392PubMedCrossRef
115.
Wang B, Yang W, Wen W et al (2010) Gamma-secretase gene mutations in familial acne inversa. Science 330:1065PubMedCrossRef
116.
117.
Williams ST, Busby RC, Demuth RJ et al (1991) Perineal hidradenitis suppurativa: presentation of two unusual complications and a review. Ann Plast Surg 26:456–462PubMedCrossRef
118.
Wolkenstein P, Loundou A, Barrau K et al (2007) Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. J Am Acad Dermatol 56:621–623PubMedCrossRef
119.
Young L, Czarnecki D (2012) The rapid onset of multiple squamous cell carcinomas in two patients commenced on ustekinumab as treatment of psoriasis. Australas J Dermatol 53:57–60PubMedCrossRef
120.
Yu CC, Cook MG (1990) Hidradenitis suppurativa: a disease of follicular epithelium, rather than apocrine glands. Br J Dermatol 122:763–769PubMedCrossRef
121.
Zarchi K, Dufour DN, Jemec GBE (2013) Successful treatment of severe hidradenitis suppurativa with anakinra. JAMA Dermatol 149:1192–1194PubMedCrossRef
122.
Zitelli KB, Zedek D, Ranganathan P et al (2013) Squamous cell carcinoma of the lip associated with adalimumab therapy for ankylosing spondylitis: a case report and review of TNF-alpha inhibitors and cutaneous carcinoma risk. Cutis 92:35–39PubMed
123.
Zouboulis CC, Bechara FG, Fritz K et al (2012) S1– Leitlinie zur Therapie der Hidradenitis suppurativa/Acne inversa. J Dtsch Dermatol Ges 10(Suppl 5):S1–S31CrossRef
Metadaten
Titel
Hidradenitis suppurativa/​Acne inversa
Ein Update
verfasst von
J. Kirschke
S. Hessam
Prof. Dr. F. G. Bechara
Publikationsdatum
02.11.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
coloproctology / Ausgabe 3/2016
Print ISSN: 0174-2442
Elektronische ISSN: 1615-6730
DOI
https://doi.org/10.1007/s00053-015-0050-7

Weitere Artikel der Ausgabe 3/2016

coloproctology 3/2016 Zur Ausgabe

Journal Club

Ligatur des intersphinktären Fistelgangs vs. Ligatur des intersphinktären Fistelgangs plus bioprothetischer Analfistelplug bei Patienten mit transsphinktären Analfisteln

Journal Club

Folgt die Therapie der chronischen Analfissur einem Algorithmus?

Update

Onkologie kolorektales Karzinom

Übersichten

Stationäre chirurgische Proktologie in Deutschland

CME

Management und Therapie des kolorektalen Frühkarzinoms

Übersichten

Proktologischer Alltag aus der Sicht eines Chirurgen

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 | Hypertonie | Nachrichten

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 | Nierenkarzinom | Nachrichten

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 | NSCLC | Nachrichten

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise